These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 12057076)
21. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721 [TBL] [Abstract][Full Text] [Related]
22. Treatment of extensive stage small cell lung cancer. Kelly K Cancer Treat Res; 2001; 105():253-76. PubMed ID: 11224990 [TBL] [Abstract][Full Text] [Related]
23. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Rigas JR Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410 [TBL] [Abstract][Full Text] [Related]
24. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057 [TBL] [Abstract][Full Text] [Related]
25. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205 [TBL] [Abstract][Full Text] [Related]
26. Indications for chemotherapy in stage IV non-small cell lung cancer. Gatzemeier U Lung Cancer; 2001 Sep; 33 Suppl 1():S109-13. PubMed ID: 11576715 [TBL] [Abstract][Full Text] [Related]
27. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer. Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931 [TBL] [Abstract][Full Text] [Related]
28. [Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer]. Souquet PJ; Gerinière L Bull Cancer; 2002 Aug; 89 Spec No():S80-4. PubMed ID: 12449035 [TBL] [Abstract][Full Text] [Related]
29. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965 [TBL] [Abstract][Full Text] [Related]
30. Antiblastic drug combinations with ifosfamide: an update. Fulfaro F; Valerio MR; Badalamenti G; Gebbia N; Russo A Oncology; 2003; 65 Suppl 2():21-30. PubMed ID: 14586143 [TBL] [Abstract][Full Text] [Related]
31. Chemoradiation in locally advanced non-small cell lung cancer. Bonomi P; Shirazi W Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987 [No Abstract] [Full Text] [Related]
32. [Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?]. Pujol JL; Choma D; Jacot W; Quantin X Bull Cancer; 2002 Aug; 89 Spec No():S85-90. PubMed ID: 12449036 [TBL] [Abstract][Full Text] [Related]
33. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W; Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747 [TBL] [Abstract][Full Text] [Related]
34. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295 [TBL] [Abstract][Full Text] [Related]
35. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939 [TBL] [Abstract][Full Text] [Related]
36. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer. Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683 [TBL] [Abstract][Full Text] [Related]
37. Recurrent ovarian cancer: how important is it to treat to disease progression? Herzog TJ Clin Cancer Res; 2004 Nov; 10(22):7439-49. PubMed ID: 15569973 [TBL] [Abstract][Full Text] [Related]
38. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620 [TBL] [Abstract][Full Text] [Related]
39. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Verma S; Ilersich AL Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745 [TBL] [Abstract][Full Text] [Related]
40. [Gemicitabine in the treatment of epithelial ovarian cancer]. Pautier P; Gutierrez M; Lhomme C Bull Cancer; 2002 Aug; 89 Spec No():S115-9. PubMed ID: 12449041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]